title: Metabolic syndrome as a peculiar target for management of prostate cancer patients.
abstract: An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified. Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors. This review evaluates this interrelation between metabolic syndrome and prostate tumor scanning in many clinical and preclinical epidemiological studies and describes possible pathogenetic biological mechanisms. Finally, this article discusses feasible clinical implications for the management, prevention, diagnosis, prognosis, and treatment of patients affected by metabolic syndrome and prostate cancer, with particular attention to the metformin action.
authors.affiliation: Centro di Riferimento Oncologico della Basilicata IRCCS, Rionero in Vulture, Italy. cinzia.conteduca@libero.it
authors.forename: Vincenza
authors.initials: V
authors.lastname: Conteduca
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Bozza
authors.forename: Raffaele
authors.initials: R
authors.lastname: Ardito
authors.forename: Michele
authors.initials: M
authors.lastname: Aieta
mesh_terms: D001823:Body Composition / Q000187:drug effects; D006801:Humans; D006946:Hyperinsulinism / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism*; D008687:Metformin / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D007004:Hypoglycemic Agents; C583557:IGF1 protein, human; D007334:Insulin-Like Growth Factor I; D008687:Metformin; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases
keywords: Androgen deprivation therapy; Carcinogenesis; Hyperinsulinemia; Insulin-growth factor-1; Metformin